Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
One-time injection of AAV8 encoding urocortin 2 provides long-term resolution of insulin resistance
Mei Hua Gao, … , Da Young Oh, H. Kirk Hammond
Mei Hua Gao, … , Da Young Oh, H. Kirk Hammond
Published September 22, 2016
Citation Information: JCI Insight. 2016;1(15):e88322. https://doi.org/10.1172/jci.insight.88322.
View: Text | PDF
Research Article Therapeutics

One-time injection of AAV8 encoding urocortin 2 provides long-term resolution of insulin resistance

  • Text
  • PDF
Abstract

Using mice rendered insulin resistant with high fat diets (HFD), we examined blood glucose levels and insulin resistance after i.v. delivery of an adeno-associated virus type 8 encoding murine urocortin 2 (AAV8.UCn2). A single i.v. injection of AAV8.UCn2-normalized blood glucose and glucose disposal within weeks, an effect that lasted for months. Hyperinsulinemic-euglycemic clamps showed reduced plasma insulin, increased glucose disposal rates, and increased insulin sensitivity following UCn2 gene transfer. Mice with corticotropin-releasing hormone type 2-receptor deletion that were rendered insulin resistant by HFD showed no improvement in glucose disposal after UCn2 gene transfer, indicating that the effect requires UCn2’s cognate receptor. We also demonstrated increased glucose disposal after UCn2 gene transfer in db/db mice, a second model of insulin resistance. UCn2 gene transfer reduced fatty infiltration of the liver in both models of insulin resistance. UCn2 increases Glut4 translocation to the plasma membrane in skeletal myotubes in a manner quantitatively similar to insulin, indicating a mechanism through which UCn2 operates to increase insulin sensitivity. UCn2 gene transfer, in a dose-dependent manner, is insulin sensitizing and effective for months after a single injection. These findings suggest a potential long-term therapy for clinical type-2 diabetes.

Authors

Mei Hua Gao, Dimosthenis Giamouridis, N. Chin Lai, Evelyn Walenta, Vivian Almeida Paschoal, Young Chul Kim, Atsushi Miyanohara, Tracy Guo, Min Liao, Li Liu, Zhen Tan, Theodore P. Ciaraldi, Simon Schenk, Aditi Bhargava, Da Young Oh, H. Kirk Hammond

×

Figure 6

Effects of UCn2 on glucose uptake.

Options: View larger image (or click on image) Download as PowerPoint
Effects of UCn2 on glucose uptake.
(A) UCn2 increases Glut4 translocatio...
(A) UCn2 increases Glut4 translocation. Left: UCn2 increases Glu4 translocation in plasma membrane (PM). Myc-tagged Glut4-expressing L6 myotubes incubated (30 minutes) with insulin (100 nM) or UCn2 peptide (200 nM). Glut4 was detected using anti-Myc antibody (green); nucleus stained using DAPI (blue). White arrows indicate plasma membrane (PM) Glut4 localization (scale bars: 10 μm). Right: PM Glut4 translocation evaluated by immunoblotting; data are normalized to Ponceau S staining. Similar to insulin, UCn2 increased Glut4 translocation (data from 5 experiments). (B) UCn2 Signaling. Left: L6 myotubes incubated (60 minutes) with insulin (Ins; 100 nM) or UCn2 peptide (100 nM). UCn2 activated AMPK, but not Akt. Right: UCn2 increases phosphorylation of AMPK (mean ± SEM, 3 experiments; data normalized to GAPDH). (C) Skeletal muscle glucose uptake. In vivo studies show that UCn2 gene transfer increased glucose uptake in skeletal muscle. P values (vs. Control, Con) from Student’s t test (paired, 2-tailed).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts